SubsidieMeestersTargeting Cancer with ERV Vaccines
InProTher is developing BreakImmune, an immunotherapy targeting HERVs to create a cancer vaccine (IPT001) that enhances immune responses against solid tumors.
Projectdetails
Introduction
InProTher (IPT) is developing a unique immunotherapy – BreakImmune – that effectively targets endogenous retroviruses (HERVs) to treat cancer.
Background
HERVs are not expressed in normal tissues, but are expressed in several major cancers, such as:
- Breast (88%)
- Prostate (90%)
- Ovarian (90%)
- Pancreatic (80%)
Thus, HERVs can be a potential target for the immune system to destroy tumor cells.
Technology
IPT technology relies on the engineering of HERVK antigens to be used as effective cancer vaccines. The administration of BreakImmune, the mutated HERVK in Ad19/MVA viral vectors, induces both strong antibody and T-cell immune responses able to destroy cancer cells in multiple cancer types.
Product
Our first product is IPT001, a first-in-class vaccine against solid cancers in combination with checkpoint inhibitors.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 12.179.813 |
Tijdlijn
| Startdatum | 1-7-2022 |
| Einddatum | 31-10-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- INPROTHER APSpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancerErVaccine aims to develop TCR-OV1, a novel TCR-T cell therapy targeting cancer-specific antigens to improve early detection and treatment outcomes for ovarian cancer patients. | EIC Accelerator | € 2.499.999 | 2024 | Details |
IntraVenous Immune BoostHEPHAISTOS-Pharma's ONCO-Boost is a groundbreaking intravenous TLR4 immunostimulant aimed at treating metastatic cancers, potentially curing 10x more patients than current therapies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer careNectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system against cancer, currently in Phase I trials to improve patient outcomes in oncology. | EIC Accelerator | € 2.499.998 | 2024 | Details |
Inhibiting resistance to immunotherapy in Oncology by targeting Netrin-1The IMMUNONET project aims to clinically test NP137, a monoclonal antibody that enhances response to immune checkpoint inhibitors in cancer patients resistant to current treatments. | EIC Accelerator | € 2.500.000 | 2022 | Details |
canceR agnOstic immUnoTherapy predIctioN blood-tEstPamGene's IOpener is an innovative diagnostic platform that predicts immune checkpoint inhibitor response from a blood sample, aiming to enhance precision medicine in cancer treatment. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancer
ErVaccine aims to develop TCR-OV1, a novel TCR-T cell therapy targeting cancer-specific antigens to improve early detection and treatment outcomes for ovarian cancer patients.
IntraVenous Immune Boost
HEPHAISTOS-Pharma's ONCO-Boost is a groundbreaking intravenous TLR4 immunostimulant aimed at treating metastatic cancers, potentially curing 10x more patients than current therapies.
First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer care
Nectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system against cancer, currently in Phase I trials to improve patient outcomes in oncology.
Inhibiting resistance to immunotherapy in Oncology by targeting Netrin-1
The IMMUNONET project aims to clinically test NP137, a monoclonal antibody that enhances response to immune checkpoint inhibitors in cancer patients resistant to current treatments.
canceR agnOstic immUnoTherapy predIctioN blood-tEst
PamGene's IOpener is an innovative diagnostic platform that predicts immune checkpoint inhibitor response from a blood sample, aiming to enhance precision medicine in cancer treatment.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeting cancer with mutanome based stem cell vaccineMUTAVAC aims to enhance IPVAC, an innovative cancer immunotherapy leveraging iPSC technology, by uncovering its mechanisms, improving immunogenicity, and paving the way for personalized cancer vaccines. | EIC Pathfinder | € 1.782.000 | 2022 | Details |
Exploration of targeting GPR56 and its cancer cell ligand as a novel immune checkpoint inhibition strategyThis project aims to develop a novel cancer therapy by targeting a new immune checkpoint receptor-ligand pair to enhance T cell activity against tumors. | ERC Proof of... | € 150.000 | 2023 | Details |
Overcoming resistance to immunotherapy: Immunostimulatory tumor-derived extracellular vesicles as multifunctional anticancer agentsIMMUNO-TEX aims to develop tumor-derived immunostimulatory extracellular vesicles to enhance antitumor immunity and overcome resistance to immune checkpoint inhibitors in poorly immunogenic tumors. | ERC Starting... | € 1.650.778 | 2023 | Details |
Synergistic Antitumor Activity of Microbiome and OMV-based in situ VaccinationThe project aims to enhance immunotherapy by combining intratumoral injection of engineered bacterial OMVs with oral Bifidobacterium to boost anti-tumor immunity and improve treatment efficacy. | ERC Proof of... | € 150.000 | 2023 | Details |
Systemic delivery of oncolytic herpes simplex viruses retargeted to cancer-specific receptors. Virus optimization and business planning.This project aims to enhance systemic delivery of innovative oncolytic herpesviruses targeting HER2-positive tumors, facilitating clinical trials and commercialization to improve metastatic cancer treatment. | ERC Proof of... | € 150.000 | 2022 | Details |
Targeting cancer with mutanome based stem cell vaccine
MUTAVAC aims to enhance IPVAC, an innovative cancer immunotherapy leveraging iPSC technology, by uncovering its mechanisms, improving immunogenicity, and paving the way for personalized cancer vaccines.
Exploration of targeting GPR56 and its cancer cell ligand as a novel immune checkpoint inhibition strategy
This project aims to develop a novel cancer therapy by targeting a new immune checkpoint receptor-ligand pair to enhance T cell activity against tumors.
Overcoming resistance to immunotherapy: Immunostimulatory tumor-derived extracellular vesicles as multifunctional anticancer agents
IMMUNO-TEX aims to develop tumor-derived immunostimulatory extracellular vesicles to enhance antitumor immunity and overcome resistance to immune checkpoint inhibitors in poorly immunogenic tumors.
Synergistic Antitumor Activity of Microbiome and OMV-based in situ Vaccination
The project aims to enhance immunotherapy by combining intratumoral injection of engineered bacterial OMVs with oral Bifidobacterium to boost anti-tumor immunity and improve treatment efficacy.
Systemic delivery of oncolytic herpes simplex viruses retargeted to cancer-specific receptors. Virus optimization and business planning.
This project aims to enhance systemic delivery of innovative oncolytic herpesviruses targeting HER2-positive tumors, facilitating clinical trials and commercialization to improve metastatic cancer treatment.